Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

334.63 -2.75 (-0.82%)
Streaming Delayed Price Updated: 2:05 PM EDT, Sep 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 565,580
Open 339.00
Bid (Size) 334.50 (2)
Ask (Size) 334.63 (1)
Prev. Close 337.38
Today's Range 333.36 - 339.17
52wk Range 249.70 - 346.85
Shares Outstanding N/A
Dividend Yield 2.55%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What the Options Market Tells Us About Amgen
Via Benzinga
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
These two stocks could be rivals in the intense GLP-1 space in the future. 
Via The Motley Fool

Performance

YTD
+12.52%
+12.52%
1 Month
+1.77%
+1.77%
3 Month
+5.18%
+5.18%
6 Month
+19.16%
+19.16%
1 Year
+25.40%
+25.40%

More News

Read More
Can These 5 Assets Skyrocket Your Portfolio?
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
Interesting Technical Analysis finding for AMGEN INC (NASDAQ:AMGN)
Via Chartmill
Where Will Amgen Be in 5 Years?
Via The Motley Fool
Behind the Scenes of Amgen's Latest Options Trends
Via Benzinga
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Amgen Unusual Options Activity For August 29
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Bull Market Strengthened, Let The Naysayers Say Nay...
Via Talk Markets
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500
Via The Motley Fool
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Via The Motley Fool
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival
Via Investor's Business Daily
Growth At Any Price (GAAP) Is A Bad Strategy. Valuation Matters.
Via Talk Markets
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Patchy But Still Bullish
Via Talk Markets
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades'
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
Eli Lilly’s Path to the Next Trillion Market Capitalization
Via MarketBeat
3 Unstoppable Dividend Stocks to Buy Right Now
Via The Motley Fool
US Stocks May Take a Breather After S&P 500's Impressive 8-Session Winning Streak: Strategist Says Market Will Hit Fresh Highs In Next 4 Weeks, But Warns Investors Of Potential Risks
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.